Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H7KF
|
|||
| Former ID |
DAP000001
|
|||
| Drug Name |
Quetiapine
|
|||
| Synonyms |
quetiapine; 111974-69-7; Quetiapine [INN:BAN]; UNII-BGL0JSY5SI; BGL0JSY5SI; CHEMBL716; 2-[2-(4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol; CHEBI:8707; C21H25N3O2S; URKOMYMAXPYINW-UHFFFAOYSA-N; 2-(2-(4-Dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)ethanol; Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-; NCGC00095911-03; Co-Quetiapine; Norsic; Quetiapina; Quetiapinum; Quetiapine hemifumarate; Ketipinor (TN); Norsic (TN); Quetiapine (INN); Seroquel (Fumarate); Seroquel (TN); 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethoxy]ethanol; 2-{[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethyl]oxy}ethanol; PD-172760
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Approved | [1], [2], [3] | |
| Alcohol dependence [ICD-11: 6C40.2; ICD-10: F10.2; ICD-9: 303] | Phase 3 | [4] | ||
| Therapeutic Class |
Antipsychotic Agents
|
|||
| Company |
AstraZeneca
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H25N3O2S
|
|||
| Canonical SMILES |
C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42
|
|||
| InChI |
1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2
|
|||
| InChIKey |
URKOMYMAXPYINW-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 111974-69-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9601, 631813, 5198881, 7980444, 8153080, 14756073, 26612817, 26749928, 29215183, 29215184, 29224074, 46504800, 48416505, 49666155, 49666758, 50064167, 50606342, 56312011, 56312821, 56394834, 57288825, 61127934, 85209878, 92308036, 93166437, 93619787, 96025142, 103195252, 103993497, 104307995, 108136177, 114919760, 124799953, 125337908, 126525318, 126653074, 126671681, 127275837, 127275838, 127275839, 127275840, 127275841, 127275842, 127275843, 129409886, 134337331, 134338691, 134339382, 134358152, 135017541
|
|||
| ChEBI ID |
CHEBI:8707
|
|||
| ADReCS Drug ID | BADD_D01888 ; BADD_D01889 | |||
| SuperDrug ATC ID |
N05AH04
|
|||
| SuperDrug CAS ID |
cas=111974697
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides vulgatus was decreased by Quetiapine hemifumarate (adjusted p-values: 4.73E-04). | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 50). | |||
| REF 3 | How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73. | |||
| REF 4 | ClinicalTrials.gov (NCT02362412) Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes. U.S. National Institutes ofHealth. | |||
| REF 5 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 6 | Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40. | |||
| REF 7 | Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.